Abstract:Introduction: The access gap for novel pharmaceuticals between China and the developed countries is a major public health issue in China. It is crucial to understand the determinants of this gap to ensure timely access to new drugs and enhance patient health. Methods: We included all new drugs approved by the US Food and Drug Administration (FDA) between 2012 and 2019, and collected their approval timings in China. Major factors of interest comprised orphan designation and expedited review pathways granted by the FDA, along with the proportion of Asian subjects in the pivotal trial supporting the FDA approval and whether the trial included study sites in China. The elapsed time from the FDA approval to the market authorization in China constituted the time-to-event outcome, and Cox proportional-hazards regression was used for multivariate analysis. Results: A total of 327 new drugs were approved by the FDA between 2012 and 2019, among which 41.3% were found to be authorized in China as of 1 November 2023. The median lag time for the mutually approved drugs was 3.5 years. The Cox model found that orphan drugs had lower likelihood of being approved in China (HR = 0.59, 95% CI 0.39–0.89; p = 0.011), while the FDA’s Breakthrough-Therapy drugs (HR = 2.33, 95% CI 1.39–3.89; p = 0.001) and Fast-Track drugs (HR = 1.58, 95% CI 1.05–2.38; p = 0.028) had shorter lag times. In the pivotal trials that supported the FDA approvals, a higher proportion of Asian subjects was associated with faster drug entry into the Chinese market (HR = 1.02, 95% CI 1.01–1.03; p < 0.001), and the inclusion of study sites in China mainland was likewise conducive to reducing the drug lag (HR = 5.30, 95% CI 3.20–8.77; p < 0.001). After the trials with China-based sites supported the FDA approvals, 77.8% of the trials also supported the subsequent approvals in China. Discussion: China’s involvement in global drug co-development can streamline clinical development, by reducing repeated trials solely in the Chinese population. This is primarily due to the openness of the Chinese drug agency towards overseas clinical data and is a positive sign that encourages global drug developers to include Chinese patients in their development plans as early as possible.

Characteristics and outcomes of the drug patent linkage system in China

Pharmaceutical patent linkage system in USA

Studies of Legal Issues Related to the Implementation of the Patent Linkage System in China

Research on pharmaceutical patents listing rules as a part of patent linkage system in United States

Analysis of Patent and Regulatory Exclusivity for Novel Agents in China and the United States: A Cohort Study of Drugs Approved Between 2018 and 2021

Perceived impact of the patent linkage system on pharmaceutical market from the viewpoint of the domestic manufacturers in South Korea

Diffusion, Convergence and Influence of Pharmaceutical Innovations: a Comparative Study of Chinese and U.S. Patents.

Trends and Characteristics of New Drug Approvals in China, 2011–2021

Pharmaceutical corporate power, traditional medical knowledge, and intellectual property governance in China

Bridging the new drug access gap between China and the United States and its related policies

Biosimilar monoclonal antibodies in China: A patent review

Pharmaceutical Industry in China: Policy, Market and IP

Evolution of drug regulations and regulatory innovation for anticancer drugs in China

Analysis on the importance of drug patent system for new drug research and development from the particularity of drug

The Implementation Status and Improvement Suggestions of Drug Patent Compulsory Licensing in China-Based on the COVID-19 Pandemic

Government-business Relations and Strategic Patenting: Evidence from China's Patent Boom

Does China's centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on double difference model

The Evolution of China's IPR System and Its Impact on the Patenting Behaviours and Strategies of Multinationals in China.

Regulatory watch: Innovative drug availability in China.

Analysis of Medicine-related Issues in New "patent Law"

Market access of Chinese patent medicine products to healthcare security system in China: implications for international integration of traditional medicine into health systems